Brand name
Beqalzi, the original
We didn’t find a savings card or cash price from Beqalzi’s maker. Ask the pharmacy for Beqalzi’s cash price. With insurance, ask what your plan charges.
Generic name: sonrotoclax
Used for: Mantle cell lymphoma that came back or didn’t respond
Ask for the cash price
Beqalzi
We didn’t find one.
Beqalzi, the original
We didn’t find a savings card or cash price from Beqalzi’s maker. Ask the pharmacy for Beqalzi’s cash price. With insurance, ask what your plan charges.
There isn’t one.
We didn’t find one.
BEQALZI is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Source: the FDA label for Beqalzi (BeOne Medicines USA, Inc.), September 25, 2026. Full label on DailyMed
Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/beqalzi/